Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE Study: VH4524184 + FTC/TAF vs DTG + 3TC in treatment-naive HIV-1
jRCT2031250635Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of VH4524184 in Human immunodeficiency virus infection type 1 (4 arms), sponsored by GSK. Primary endpoint: Percentage of participants achieving HIV-1 RNA <50 copies/mL at Month 12 (FDA Snapshot). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
VH4524184
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2031250635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250635.